XBITライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:39):

Stats
本日の出来高	69 494.00
平均出来高	74 175.00
時価総額	243.61M
EPS	$-0.420 ( 2024-03-13 )
次の収益日	( $0 ) 2024-05-08
Last Dividend	$2.50 ( 2021-07-15 )
Next Dividend	$0 ( N/A )
P/E	-9.88
ATR14	$0.0500 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Simard John	Buy	2 470 355	Convertible Loan Agreement
2023-06-23	Waldin Jan-paul	Buy	25 000	Director Stock Option
2023-06-23	Libby Peter	Buy	25 000	Director Stock Option
2023-06-23	Macadam Donald H.	Buy	25 000	Director Stock Option
2023-06-23	Mckenzie W Thorpe	Buy	25 000	Director Stock Option

INSIDER POWER
97.98
Last 100 transactions
Buy: 4 116 188 \| Sell: 11 979 897

ボリューム相関

長: -0.16 (neutral)

短: 0.27 (neutral)

Signal:(63.681) Neutral

XBiotech Inc 相関

10 最も正の相関
VVOS	0.88
BPRN	0.871
BELFA	0.856
CGO	0.845
CNTY	0.845
PASG	0.84
APLD	0.838
DORM	0.831
BBCP	0.815
ATNX	0.812

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

XBiotech Inc 相関 - 通貨/商品

0.33
( neutral )

-0.33
( neutral )

0.00
( neutral )

0.42
( neutral )

0.23
( neutral )

-0.41
( neutral )

XBiotech Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-1.74M (0.00 %)
EPS:	$-0.810

FY	2023
収益:	$0
総利益:	$-1.74M (0.00 %)
EPS:	$-0.810

FY	2022
収益:	$4.01M
総利益:	$3.36M (83.77 %)
EPS:	$-1.080

FY	2021
収益:	$18.39M
総利益:	$12.57M (68.36 %)
EPS:	$-0.580

Financial Reports:

No articles found.

XBiotech Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

XBiotech Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$2.50	2021-07-15
Last Dividend	$2.50	2021-07-15
Next Dividend	$0	N/A
Payout Date	2021-07-23
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$2.50	--
Avg. Dividend % Per Year	1.55%	--
Score	0.63	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.63

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2021	$2.50	15.50%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-9.37	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.108	1.200	-3.60	-4.32	[0 - 0.3]
returnOnEquityTTM	-0.108	1.500	-2.31	-3.47	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	33.07	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	32.94	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	32.79	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.615	2.00	-0.205	-0.410	[0 - 30]
freeCashFlowPerShareTTM	-0.627	2.00	-0.314	-0.627	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.334	1.000	7.76	7.76	[0.2 - 0.8]
operatingProfitMarginTTM	-14.32	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0115	0.800	-3.26	-2.61	[0.5 - 2]
Total Score				-0.390

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-9.75	1.000	-1.086	0	[1 - 100]
returnOnEquityTTM	-0.108	2.50	-1.487	-3.47	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.627	2.00	-0.209	-0.627	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.615	2.00	-0.205	-0.410	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.275	1.500	-5.17	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-7.15	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.34

XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.